Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Forte Biosciences, Inc.
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, ≥ 2 years of age
Clinical diagnosis of atopic dermatitis as defined by Hanifin and Rajka criteria that has been present for ≥ 3 months before the screening visit
Investigator Global Assessment (IGA) score of 2 (mild) or 3 (moderate) at Screening and Baseline/Day 1 using the validated IGA scale for atopic dermatitis
EASI score ≥ 5 at the screening and the Baseline visit
5% to 30% (inclusive) body surface area of atopic dermatitis involvement at the screening and the baseline visit
You may not be if
Previous treatment within 4 weeks prior to the baseline visit with any of the following:
Immunosuppressive or immunomodulating systemic drugs such as systemic (intravenous, oral, intra-articular or intramuscular) corticosteroids, azathioprine, methotrexate, cyclosporine
Phototherapy or photo chemotherapy for atopic dermatitis
Previous treatment within 1 week prior to the baseline visit with any of the following:
Topical corticosteroids (does not include inhaled, intranasal or ophthalmic) or topical calcineurin inhibitors
Topical phosphodiesterase type 4 (PDE4) inhibitor
Use of emollients other than provided for the study
Bleach baths
Within 8 weeks or 5 half-lives (if known), whichever is longer, prior to the baseline visit with Janus kinase inhibitors or other investigational drug
Within16 weeks or 5 half-lives, whichever is longer, prior to the baseline visit with dupilumab or other biologic agent to treat atopic dermatitis
Within 1 year prior to the baseline visit with any live bacterial therapy
Pregnant (or planning to become pregnant during the period of the study) or lactating females
